Cargando…

CD133(+)CD24(lo) defines a 5-Fluorouracil-resistant colon cancer stem cell-like phenotype

The chemotherapeutic agent 5-Fluorouracil (5-FU) is the most commonly used drug for patients with advanced colon cancer. However, development of resistance to 5-FU is inevitable in almost all patients. The mechanism by which colon cancer develops 5-FU resistance is still unclear. One recently propos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paschall, Amy V., Yang, Dafeng, Lu, Chunwan, Redd, Priscilla S., Choi, Jeong-Hyeon, Heaton, Christopher M., Lee, Jeffrey R., Nayak-Kapoor, Asha, Liu, Kebin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346671/ https://www.ncbi.nlm.nih.gov/pubmed/27659530 http://dx.doi.org/10.18632/oncotarget.12168

Ejemplares similares

Osteopontin Blockade Immunotherapy Increases Cytotoxic T Lymphocyte Lytic Activity and Suppresses Colon Tumor Progression
por: Klement, John D., et al.
Publicado: (2021)

The NF-κB p65 and p50 homodimer cooperate with IRF8 to activate iNOS transcription
por: Simon, Priscilla S., et al.
Publicado: (2015)

Ceramide mediates FasL-induced caspase 8 activation in colon carcinoma cells to enhance FasL-induced cytotoxicity by tumor-specific cytotoxic T lymphocytes
por: Coe, Genevieve L., et al.
Publicado: (2016)

Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes
por: Lu, Chunwan, et al.
Publicado: (2019)

5-Fluorouracil Suppresses Colon Tumor through Activating the p53-Fas Pathway to Sensitize Myeloid-Derived Suppressor Cells to FasL(+) Cytotoxic T Lymphocyte Cytotoxicity
por: Yang, Yingcui, et al.
Publicado: (2023)

Myeloid-Derived Suppressor Cells Produce IL-10 to Elicit DNMT3b-Dependent IRF8 Silencing to Promote Colitis-Associated Colon Tumorigenesis
por: Ibrahim, Mohammed L., et al.
Publicado: (2018)

Restoring FAS Expression via Lipid-Encapsulated FAS DNA Nanoparticle Delivery Is Sufficient to Suppress Colon Tumor Growth In Vivo
por: Merting, Alyssa D., et al.
Publicado: (2022)

Expression of CD133 and CD24 and their different phenotypes in urinary bladder carcinoma
por: Farid, Rola M, et al.
Publicado: (2019)

Proteasomes Are Critical for Maintenance of CD133+CD24+ Kidney Progenitor Cells
por: Al-Marsoummi, Sarmad, et al.
Publicado: (2023)

Evaluation of Cancer Stem Cell Markers CD133, CD44, CD24: Association with AKT Isoforms and Radiation Resistance in Colon Cancer Cells
por: Sahlberg, Sara Häggblad, et al.
Publicado: (2014)

Cancer stem cells CD133 and CD24 in colorectal cancers in Northern Iran
por: Nosrati, Anahita, et al.
Publicado: (2016)

THE CD133-POSITIVE COLON CANCER CELL PHENOTYPE IS MORE INTERACTIVE WITH THE TUMOR MICROENVIRONMENT COMPARED TO CD133-NEGATIVE CELL
por: Chao, Celia, et al.
Publicado: (2011)

DNA alterations in Cd133+ and Cd133- tumour cells enriched from intra-operative human colon tumour biopsies
por: Cervantes-Madrid, Diana, et al.
Publicado: (2017)

Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation
por: Moorman, Hannah R., et al.
Publicado: (2020)

Prospectively Isolated Cancer-Associated CD10(+) Fibroblasts Have Stronger Interactions with CD133(+) Colon Cancer Cells than with CD133(−) Cancer Cells
por: Cui, Lin, et al.
Publicado: (2010)

In vitro characterization of CD133(lo) cancer stem cells in Retinoblastoma Y79 cell line
por: Nair, Rohini M., et al.
Publicado: (2017)

Oxytetracycline have the therapeutic efficiency in CD133(+) HCC population through suppression CD133 expression by decreasing of protein stability of CD133
por: Song, Yeonhwa, et al.
Publicado: (2018)

CD133-regulated nucleophosmin expression in human colon cancer cells
por: Kim, Kun, et al.
Publicado: (2014)

Role of CD44(high)/CD133(high) HCT-116 cells in the tumorigenesis of colon cancer
por: Zhou, Jin-Yong, et al.
Publicado: (2016)

Differential number of CD34+, CD133+ and CD34+/CD133+ cells in peripheral blood of patients with congestive heart failure
por: Fritzenwanger, M, et al.
Publicado: (2009)

Brca1 breast tumors contain distinct CD44(+)/CD24(- )and CD133(+ )cells with cancer stem cell characteristics
por: Wright, Mollie H, et al.
Publicado: (2008)

Epigenetic regulation of apoptosis and cell cycle regulatory genes in human colon carcinoma cells
por: Paschall, Amy V., et al.
Publicado: (2015)

Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells
por: Friel, Anne M, et al.
Publicado: (2010)

Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations
por: Grasso, Carole, et al.
Publicado: (2016)

Response to Stress in Early Tumor Colonization Modulates Switching of CD133-Positive and CD133-Negative Subpopulations in a Human Metastatic Colon Cancer Cell Line, SW620
por: Hsu, Chih-Sin, et al.
Publicado: (2013)

CD24 Expression Is Increased in 5-Fluorouracil-Treated Esophageal Adenocarcinoma Cells
por: Jiménez, Pilar, et al.
Publicado: (2017)

Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis
por: Durko, L., et al.
Publicado: (2017)

CD133 Expression and Identification of CD133/nestin Positive Cells in Rhabdomyosarcomas and Rhabdomyosarcoma Cell Lines
por: Sana, Jiri, et al.
Publicado: (2011)

Cobalt ferrite nanoparticle for the elimination of CD133+CD44(+) and CD44(+)CD24(−), in breast and skin cancer stem cells, using non-ionizing treatments
por: Khalili Najafabad, Bahareh, et al.
Publicado: (2023)

In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133(high) to CD133(low) phenotype and reduces the CD133-related invasiveness
por: Brugnoli, Federica, et al.
Publicado: (2013)

Corrigendum to “Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis”
por: Durko, L., et al.
Publicado: (2017)

CD133 Role in Oral Carcinogenesis
por: Luna, Ealber Carvalho Macedo, et al.
Publicado: (2020)

Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma
por: Yu, Ji-wei, et al.
Publicado: (2010)

Gold nanoparticles conjugated with anti-CD133 monoclonal antibody and 5-fluorouracil chemotherapeutic agent as nanocarriers for cancer cell targeting
por: Mohd-Zahid, Manali Haniti, et al.
Publicado: (2021)

Viability and intracellular nitric oxide generation in the umbilical cord blood CD34(+)CD133(–) and CD34(+)CD133(+) cell populations exposed to local anaesthetics
por: Kulińska, Karolina I., et al.
Publicado: (2021)

Augmented CD133 expression in distal margin correlates with poor prognosis in colorectal cancer
por: Pradhan, Tapas, et al.
Publicado: (2019)

PKH(high)/CD133+/CD24− Renal Stem-Like Cells Isolated from Human Nephrospheres Exhibit In Vitro Multipotency
por: Bombelli, Silvia, et al.
Publicado: (2020)

CD133 antigen expression in ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2009)

CD133, Selectively Targeting the Root of Cancer
por: Schmohl, Jörg U., et al.
Publicado: (2016)

CD133 in brain tumor: the prognostic factor
por: Li, Bin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_76998f2498komumk6d33guimb4